Two Acts, One Geopolitical Moment
AI is in Every Pharma Strategy Deck
Long-acting Injectable Formulations
Electronic Logs - The next phase of execution maturity in pharma
From Snapshots to Movies
EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Datamonitor
Analyst
include the changing patent laws as countries aim to become more TRIPS compliant with India updating its law recently and China in the process of doing so through the WTO Increasing globalization of the generics market with Indian companies becoming involved in Europe and the US and vice versa will also provide an opportunity for generics companies
Research Insights
A systematic evaluation of Mycobacterium tuberculosis Genome-Scale Metabolic Networks
Metabolism underpins the pathogenic strategy of the causative agent of TB Mycobacterium tuberculosis Mtb and therefore metabolic pathways have recently reemerged as attractive drug targets A powerful approach to study Mtb metabolism as a whole
Case Studies
Unusual Drug Response And Hemodynamics In VA – ECMO : A Drug Case Study
Abstract Maintaining higher sedation in patients undergoing ECMO therapy is crucial Currently no definite sedation strategy has been proposed in the literature as the pharmacokinetics of the medications in these patients is still not clear We would like to report a case of a patient with uncontrollable diverse clinical response to medications during arteriovenou
Techno Trends
Rozlytrek® (entrectinib), The First Tumour-Agnostic Therapy Discovered
Rozlytrek entrectinib the first tumouragnostic therapy discovered for the treatment of patients with NTRK fusionpositive locally advanced or metastatic solid tumours in adult and paediatric patients who have either progressed following prior therapies or who have no acceptable standard therapies
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Therapeutic Peptides
Rienzi Mosqueda is a dedicated writer specialising in life science, health, and pharma content. With a passion for clear, engaging writing, Rienzi provides fresh perspectives on each topic. His ability to simplify complex ideas makes the articles valuable for readers of all backgrounds. As an emerging voice, Rienzi Mosqueda is committed to sharing knowledge and sparking discussions through their impactful writing.
A BITTER PILL: Exploring the Realm of Drug Counterfeiting
Stephen Ward is Pinkerton’s the Vice President of East Coast USA. Established in 1850, Pinkerton National Detective Agency offers organizations in today’s modern age, a range of corporate risk management services from security consulting and investigations to executive protection, employment screening and protective intelligence.
Angelo Krizmanic is Pinkerton’s Vice President of Asia Pacific. Established in 1850, Pinkerton National Detective Agency offers organizations in today’s modern age, a range of corporate risk management services from security consulting and investigations to executive protection, employment screening and protective intelligence.
Quercetin - A Super Food For Therapeutic Interventions
Mohini Sikarwar is a PhD Scholar at Centre for Development of Biomaterials, Sharda University, Greater Noida, India. Her research is focusing on advanced drug delivery systems with a commitment to enhancing therapeutic efficacy of poorly water-soluble drug for Leishmaniasis treatment. She is aiming to revolutionise the current treatment methods of Kala azar using drug delivery approaches.
Dr. Piyush Kumar Gupta is currently head of the Centre for Development of Biomaterials at Sharda University, Greater Noida, India. His area of expertise belongs to Biomaterials, Pharmaceutics, and Nanotoxicology. He has published 143 SCIE and Scopus-indexed peer-reviewed articles and 7 book chapters in his area of expertise. He has been bestowed with several International or National awards.
Metabolic Stability
Rajesh Sonti is working as an Assistant Professor since Feb 2020 in Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER)-Hyderabad. He completed PhD from IISc, Bangalore and later worked as a post doc in University of Basel and EPFL-Lausanne for 6.5 years.
Venkata Rao Kaki is working as an Assistant Professor in Department of Chemical Sciences (medicinal chemistry/natural products),NIPER-Hyderabad. He completed PhD from Panjab university, Chandigarh. He has 4 years industrial and 8 years of academic experience.
Siva Nageswara Rao Gajulais pursuing PhD in Department of Pharmaceutical Analysis, NIPER-Hyderabad. He is working in the scientific areas:Drug Metabolism and Pharmacokinetics (DMPK), biomarkers and drug-drug interactions. He did M.S. (Pharm.) in department of pharmaceutical Analysisfrom NIPER-Ahmedabad.
Pursued M.S. (Pharm.), National Institute of Pharmaceutical Education and Research (NIPER)
Megha Sajakumar Pillai pursued M.S. (Pharm.) in department of pharmaceutical Analysis, NIPER-Hyderabad. She is currently pursuing PhD in NIPER-Ahmedabad.
Architecting the Modern MICC for Life Sciences GCCs
Tanshuman Das is a life sciences technology and commercial leader with 17+ years of experience across pharmacovigilance, AI, CRO services and drug safety technology. He leads Sales & Marketing at Synapmed and focuses on translating AI and intelligent automation into practical, scalable solutions for life sciences organisations.
press releasesRead more...
Merck Opens €300 Million Asia-Pacific Bioprocessing Center in Daejeon, South Korea
Merck a leading science and technology company today opened its new AsiaPacific Bioprocessing Production Center in Daejeon South Korea The center represents an investment of more than million the companys largest Life Science investment in AsiaPacific to date
Flagship Pioneering Forms Etcelera to Move Drug Discovery from Probability to Prediction
Flagship Pioneering a scientific innovation engine for transformative platforms and products today announced the formation of Etcelera a company created by the merger of the platforms of Cellarity Cellarity Platform Inc Etiome and Empress Therapeutics to pioneer causal intelligence in human biology...
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma
Shanghai Junshi Biosciences Co Ltd a leading innovationdriven biopharmaceutical company dedicated to the discovery development and commercialization of novel therapies announced that the supplemental new drug application for the companys product toripalimab injection subcutaneous injection
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia
HUTCHMED China Limited today announces that the US Food and Drug Administration FDA has granted Orphan Drug Designation to sovleplenib for the treatment of primary immune thrombocytopenia ITP an autoimmune disorder that can lead to increased
Transpharmation Ltd. Announces Strategic Acquisition of OrganoTherapeutics SARL
Were delighted to announce the strategic acquisition of OrganoTherapeutics SARL a leader in patientderived organoid technologies that advance the discovery and development of novel therapies for neurodegenerativeCNS disorders
EVERSANA Expands Global Commercialization and AI-Powered HEOR Capabilities with Acquisition of U.K.-based Estima Scientific
EVERSANA a global provider of modern AIpowered commercial services for the biopharmaceutical industry today announced the acquisition of Estima Scientific an innovative Londonbased health economics and outcomes research HEOR technology and services company
EventsRead more...
02 - 04
Nov 2026Pharma Forum EMEA 2026
Dom Pedro Lisboa Hotel, Lisbon...
02 - 04
Nov 2026Cancer R&D 2026
Houston, TX, USA
03 - 05
Nov 202610th Dermatology Drug Development
Boston, Massachusetts at The C...
03 - 04
Nov 2026PDA Aseptic Processing of Biopharma Conference
Sheraton Grand Incheon Hotel,...
04 - 05
Nov 2026Advanced Therapies USA
Hynes Convention Center, Bosto...
05 - 05
Nov 2026PDA Contamination Control Strategy Workshop
Sheraton Grand Incheon Hotel,...
09 - 11
Nov 202611th Microbiome Movement USA Summit
The Colonnade Hotel, Boston, M...
10 - 11
Nov 2026Extractables & Leachables Europe
Parkhotel Schӧnbrunn, Vienna,...
LATEST NEWSRead more...
Edison Scientific Enters into Agreement with Pfizer to Advance Drug Research and Development
Edison Scientific has entered into an agreement with Pfizer to introduce its Edison AI Platform and AI scientist Kosmos across Pfizers biopharmaceutical research and development activities The collaboration will combine Edison Scientifics artificial intelligence AI technology with Pfizers scientific...
Appian and PSI CRO Partner to Advance AI-driven Clinical Trial Operations
Appian and PSI CRO have entered into a strategic partnership to introduce an artificial intelligence AIpowered solution for clinical trial site identification and selection The solution is now live and is designed to automate site selection across different therapeutic areas medical conditions and...
Adalvo Acquires Romiplostim Biosimilar from Enzene
Adalvo has acquired a romiplostim biosimilar programme from Enzene expanding its portfolio of biosimilars and strengthening its presence in complex biological medicines The programme references Nplate romiplostim a medicine used to treat immune thrombocytopenia ITP in adults and children with chroni...
Twist Bioscience Launches Express Screening Antibodies for Faster Characterisation
Twist Bioscience has expanded its antibody production and characterisation portfolio with the launch of Twist Express Screening Antibodies a service designed to help researchers evaluate large numbers of antibody candidates more quickly The service uses a highthroughput cellfree production process t...
Astellas Enters into Agreement with Audax for Immuno-Oncology Candidate DAX-044
Astellas Pharma and Audax Biosciences have entered into an exclusive option and licence agreement for DAX an investigational antibodycytokine fusion being developed for cancer immunotherapy DAX is designed to deliver interleukin IL an immuneactivating protein more selectively to the tumour microenvi...
Sumitomo Pharma’s Enzomenib Receives Breakthrough Therapy Designation for Relapsed or Refractory KMT2A-Rearranged Acute Leukaemia
Sumitomo Pharma America has announced that the US Food and Drug Administration FDA has granted Breakthrough Therapy designation to enzomenib DSP for treating patients with relapsed or refractory acute leukaemia carrying a KMTA gene rearrangement
